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Background. We report on 19 cases of giant cell tumor of bone (GCT) aﬀecting the spine or sacrum and evaluate the outcome of
diﬀerent treatment modalities. Methods. Nineteen patients with GCT of the spine (n = 6) or sacrum (n = 13) have been included
inthisstudy.Themeanfollowupwas51.6months.TensacralGCTweretreatedbyintralesionalproceduresofwhich4alsoreceived
embolization, and 3 with irradiation only. All spinal GCT were surgically treated. Results. Two (15.4%) patients with sacral and
4 (66.7%) with spinal tumors had a local recurrence, two of the letter developed pulmonary metastases. One local recurrence
of the spine was successfully treated by serial arterial embolization, a procedure previously described only for sacral tumors. At
last followup, 9 patients had no evidence of disease, 8 had stable disease, 1 had progressive disease, 1 died due to disease. Six
patients had neurological deﬁcits. Conclusions. GCT of the axial skeleton have a high local recurrence rate. Neurological deﬁcits are
common. En-bloc spondylectomy combined with embolization is the treatment of choice. In case of inoperability, serial arterial
embolization seems to be an alternative not only for sacral but also for spinal tumors.
1.Introduction
Giant cell tumor of bone (GCT) is a rare skeletal lesion that
typically arises in the metaepiphyseal ends of long bones
[1–3]. Its peak incidence is between 30 to 40 years of age.
Although classiﬁed as benign it shows locally aggressive
behavior [4–7].
The treatment is mainly surgical and consists of intrale-
sional curettage of the tumor followed by bone cement
packing or bone grafting of the defect. Depending on the
surgical procedure the local recurrence rate signiﬁcantly
varies from approximately 10% to 40% and is the lowest if
high-speed burring of the margins after curettage and bone
cement packing is used [2, 8–11].
Whereas these treatments are nowadays well accepted for
“typical” GCT, recommendations on treating tumors of rare
localizations such as small bones, pelvis, spine, or sacrum
are still unclear [1–3, 12–18]. Especially tumors of the axial
skeleton, mainly spine and sacrum, seem to be particularly
complicated to treat. This is most likely due to the limited
surgical accessibility and proximity to spinal cord and nerve
roots. Possible treatments range from intralesional resection
to en bloc spondylectomy with various adjuncts such as
irradiation or arterial embolization [12, 15, 19–25].
The literature provides only small case series of spine or
sacral GCT with mostly short follow-up periods [12, 15, 19–
25]. In this report we add our experience with treatment of
GCT aﬀecting the axial skeleton, and discuss our results with
respect to the current literature.
2.MaterialsandMethods
Nineteen patients with histologically certiﬁed benign GCT
of the axial skeleton have been included in this study. They
were collected from the GCT database of the corresponding
author that includes 282 patients since 1980. The stored
information was received from patient records, surgical
protocols,andhistologicalandradiologicalﬁndings. Thelast
followup was done via personal contact in the outpatient
clinic of the senior author at a mean of 51 (15–133) months.2 Sarcoma
13 tumors were located in the sacrum, 6 tumors were located
inthemobilespine:4thoracicand2lumbar.Foranoverview
of the patient collective see Table 1.
2.1. Primary Treatment. For detailed information see
Table 1. All 6 patients with GCT of the mobile spine (cases
1–6) were primarily surgically treated by intralesional pro-
cedures after preoperative embolizasion. One patient (case
1) received a partial resection through a ventral approach,
ﬁlling of the defect with bone graft and ventral stabilization.
One patient (case 2) was treated through a dorsal approach
by intralesional curettage, burring of the margins, bone
grafting plus bone cement packing, and dorsal stabilization.
Two thoracic tumors (cases 3 and 4) were treated by
dorsoventral procedures with dorsal instrumentation and
stabilization followed by intralesional (due to spinal cord
displacement) tumor resection. Both lumbar tumors (cases
5 and 6) were treated by dorsoventral spinal body resection
and reconstruction with a vertebral body replacement ﬁlled
with autologue bone graft (Figure 1). Due to the soft
tissue component with invasion of the right psoas muscle
and displacement of the spinal cord, both resections were
considered as intralesional.
The patients with sacral tumors (cases 7–19) were either
treated primarily surgically (cases 7–16) or with external
beam irradiation (EBI) only (cases 17–19). Five patients
(cases 7–11) were treated by intralesional curettage and bone
cement packing (Figure 2). One patient (case 12) received
partial resection, mainly of the soft tissue component,
followed by chemotherapy and EBI. Four patients (cases
13–16) received preoperative selective arterial embolization
(SAE) followed by intralesional curettage and bone graft
(case 13) or curettage and bone cement packing (case 14), in
2casescombinedwithpostoperativeEBI(cases15-16).Cases
15 and 16 presented with spinal cord compression, thus only
partial removal of the tumor was possible. Three patients
(cases 17–19) were not operated on, but were solely treated
by EBI (cases 17 and 18) which in one case was followed by
SAE three months later (case 19).
3. Results
The mean age at ﬁrst diagnosis of all patients was 27.4
(range 17 to 61) years. Patients with aﬀection of the sacrum
were slightly older (mean 29.2 years) than the spine patients
(mean 23.5 years). 13 patients were female, 6 were male.
Three out of six spinal patients (cases 3, 5, 6) and two out
of thirteen sacral patients (cases 16 and 19) had neurological
deﬁcits at initial presentation (Table 1).
Concerning the radiological ﬁndings according to Cam-
panacci and Enneking [2, 26] all 15 patients for whom the
respective information was available presented with stage III
lesions. The same 15 patients presented with a soft tissue
component.
3.1. Local Recurrences. The mean period from primary
treatment to detection of the recurrence was 11.3 (7–21)
months; 6 of the 7 recurrences developed within the ﬁrst
year (see Table 1). All patients were seen every 3 month
for the ﬁrst two years postoperatively and evaluated by X-
rays. If there were any suspicious ﬁndings or a worsening of
symptoms additional diagnostics such as MRI or CT were
performed. Until the 5th postoperative year patients were
seen every 6 months and from then on once a year.
Four of the spine cases developed a local recurrence
(cases 1, 3, 4, 6) of which one case (case 4) developed
two recurrences. Case 1 was initially treated by intrale-
sional tumor resection and bone grafting through a ven-
tral approach. The recurrence was successfully treated by
another intralesional tumor resection and bone grafting,
again through a ventral approach. He developed a loss of
sensory function and paresis at Th 9 level, with a persistent
footdrop right after surgery. Cases 3 and 4 were initially
treated by partial intralesional vertebral body resection,
bone grafting, and dorsal stabilization through a combined
dorsoventral approach. The recurrence of case 3 was treated
byintralesionaltumorresection,decompressionofthespinal
cord, and elongation of the internal ﬁxation through a dorsal
approach. She developed pulmonary metastases two month
later and additionally received chemotherapy and irradiation
(see below) resulting in stable disease. The recurrence of
case 4 was treated by intralesional tumor resection through
a ventral approach but developed another recurrence six
months later. She was then treated by intralesional retroperi-
toneal partial tumor resection and bone cement packing.
Intraoperatively she had a severe blood loss due to laceration
of the aorta. She was scheduled for EBI but eventually died
13 days after the last operation due to respiratory failure.
Case 6 was primarily treated by dorsoventral intralesional
spondylectomy, dorsal stabilization, and cage implantation
with bone grafting. Due to inﬁltration of the psoas mus-
cle and invasion of the spinal canal this resection was
still considered intralesional. He presented with a huge
local recurrence surrounding the abdominal aorta causing
sensitive disorders. He was considered as inoperable and
successfully treated by a series of SAE directly after detection
of the recurrence, 1 months and 6 months later. Each SAE
was done until complete devascularization of the tumor
vessels was achieved (Figure 3). At last followup he presented
with a stable disease without neurological impairments but
still needing daily pain medications. Since the recurrence,
he additionally has been receiving oral bisphosphonates
(clodronate 800mg) twice a day.
Three of the sacrum cases developed a local recurrence
(cases 7, 9, 17). The ﬁrst two were primarily treated by
intralesional curettage and bone cement packing, the last by
EBI only. Case 7 developed a local infection 1 month after
initial surgery that was cured by repeated curettage and bone
cement packing in combination with systemic antibiotics.
After this second operation he suﬀered from irritation of
the left S1 nerve root resulting in neurologic claw toes. He
presented with a soft tissue recurrence without aﬀection
of the bone and was successfully treated by resection of
the respective tissue. The recurrence of case 9 was treated
by preoperative SAE and intralesional partial resection but
was progressive 6 months later and again treated by SAE.
Another 6 months later the tumor was again progressiveSarcoma 3
Table 1: (a) Giant cell tumors of the mobile spine. (b) Giant cell tumors of the sacrum.
(a)
Number Sex Age Site/neuro status FU Primary treatment Rec. Treatment rec. Met. Outcome
1M 1 8 Y T h 6 / O K 2 7 M
Ventral: intral. res.,
bone graft, ventral
stabilization
8M
Ventral: intral.
res. Th6–Th7,
bone graft
NED
Loss of sensory function
and paresis at Th9 level,
footdrop right
2F 1 7 Y
Th12 / encasing
of left nerve root
with sensory
disorders
98M
dorsal: intral.
curettage, dorsal
instr. Th10 – L2,
transection of
nerve root Th12 +
bone graft, bone
cement
NED
3F 2 3 Y
Th10/inﬁltration
of spinal canal
with initial
paresthesias
83M
Dorsoventral:
intral. partial res.
Th10, dorsal instr.
Th9–11, bone graft
11M
Dorsal: intral.
partial res.
Th9–Th11,
decompres-
sion of spinal
canal,
extension of
instrumenta-
tion
Th8–Th12
13M SD
Recovery from
paresthesias but local
progress, destruction of
Th7–Th9, encasing of
aorta, displacement of
cava and heart,
pleural/pericardial
eﬀusion, bipulmonary
met. treated by chemo
(4 cycles Ifosfamid,
Cisplatin) and EBI
46Gy over 1M. last FU
constant unresectable
met., decrease of local
tumor, pregnant
4 F 26 Y Th11/OK 24M
Dorsoventral:
intral. partial res.
Th11, dorsal instr.
Th10–Th12, bone
graft (rib)
7M/13M
Ventral: intral.
res., bone
cement,
laceration of
aorta, severe
bleeding
D
EBI started after rec.,
death due to pulmonary
failure 13 days after last
surgery
5F 2 7 Y
L4/inﬁltration of
right
psoas/spinal
canal, encasing
right nerve root
with sensory
disorders
32M
Dorsoventral:
spondylectomy L4,
intral. res. soft
tissue component,
dorsal instr. L3–
L5, titanium cage
interposition, bone
graft
16M NED
Oral clodronate (800
mg 2/d), since resection
of bipulmonary met.,
free of complaints
6M 3 0 Y
L4/inﬁltration of
right psoas
muscle and
spinal canal
causing weakness
of right
quadriceps
45M
Dorsoventral:
intral.
spondylectomy L4,
intral. res. soft
tissue component,
dorsal instr. L3–L5,
titanium cage
interposition, bone
graft
9M
No surgery,
serial SAE
until complete
devasculariza-
tion 3 times
(directly, 1 and
6Mlater)
SD
Local rec. encasing aorta
with loss of sensory
function at L4 level,
after serial SAE
complete recovery of
neurological functions,
slight regression of
tumor on MRI, since
rec. daily oral pain
medication and
clodronate (800 mg
2/d), able to work full
time in oﬃce
FU: followup, rec.: recurrence, met.: metastasis, M: male/months, F: female, Y: years, Th: thoracal spine, L: lumbar spine, intral.: intralesional, res.: resection,
instr.: instrumentation, EBI: external beam irradiation, preop.: preoperative, SAE: selective arterial embolization, Gy: Gray, NED: no evidence of disease, SD:
stable disease, D: dead due to disease.4 Sarcoma
(b)
Number Sex Age Site /neuro status FU Primary treatment Rec. Treatment rec. Outcome
7 F 25 Y Sacrum/OK 133M Intral. curettage,
bone cement 11M Resection of soft
tissue recurrence NED
Local infection after
initial surgery cured
by repeated curettage
and cementation plus
systemic antibiotics,
subsequently
irritation of left S1
nerve root causing
claw toes
8 F 19 Y Sacrum/OK 124M Intral. curettage,
bone cement NED
Local infection after
initial surgery cured
by repeated curettage
and cementation plus
systemic antibiotics,
ﬁnal FU free of
complaints
9M 2 0 Y sacrum, aﬀection
of SI joint/OK 20M Intral. curettage,
bone cement 12M Preop. SAE, partial
intral. res. PD
Local progress 6M
after rec. treated by
SAE, another progress
after again 6M
treated by EBI 30Gy
over 1M without
eﬀect, at last FU free
of pain but progress
with incomplete
p a r e s i so fl e f tf o o t .
Scheduled for
denosumab treatment
10 F 20 Y
Sacrum,
inﬁltration of
spinal canal/no
neurological
deﬁcits
62M Intral. curettage,
bone cement SD
Stable left-over tumor
tissue after partial
removal, oral
clodronate (800 mg
2/d) over 1 Y, last FU
free of complaints
11 F 61 Y Sacrum/OK 24M
Intral. curettage,
laminectomy
S1–S4, bone
cement
NED
Conus/cauda
syndrome since
surgery
12 F 18 Y Sacrum, crossing
of midline/OK 49M
Intral. partial res.
mainly of soft
tissue component,
chemotherapy
(CWS-96 study
ifosfamid,
vincristine,
adriamycin), EBI
50Gy over 1M
SD Free of complaints
13 M 24 Y Sacrum/OK 88M
Preop. SAE,
ligation of left and
right internal iliac
vessels and median
sacral artery,
curettage, bone
graft
NED
Local infection after
initial surgery cured
by repeated curettage
and cementation plus
systemic antibiotics,
ﬁnal FU free of
complaints
14 F 32 Y
Sacrum,
inﬁltration of
ilium/OK
15M
Preop. SAE,
curettage, bone
cement
NED Free of complaintsSarcoma 5
(b) Continued.
Number Sex Age Site /neuro status FU Primary treatment Rec. Treatment rec. Outcome
15 M 20 Y
Sacrum,
inﬁltration of
spinal canal and
spinal cord
compression/no
neurological
deﬁcits
28M
Preop. SAE, intral.
partial curettage,
bone cement, EBI
with a special
particle accelerator
at the DKFZ
(“german cancer
research center” in
Heidelberg,
Germany) 66Gy
over 1M
SD
Free of complaints,
regression of tumor
on MRI
16 M 28 Y
Sacrum, stenosis
of spinal canal/
conus/cauda
syndrome
51M
Preop. SAE, partial
curettage, bone
cement, EBI 60Gy
over 1M
NED
Persistent
rectum/bladder
dysfunction, gluteal
dysesthesia
17 F 28 Y Sacrum large/OK 36M No surgery, EBI
50Gy over 1M 21M No surgery, EBI
50Gy over 1M SD
Regression after ﬁrst
EBI but progress after
21M again treated by
EBI + systemic
interferon alpha,
ongoing oral
clodronate (800 mg
2/d) intake since rec.
18 F 29 Y
Sacrum, large,
crossing of
midline/OK
24M No surgery, EBI
55Gy over 1M SD
slight regression of
tumor on CT, free of
complaints
19 F 56 Y
Sacrum/pain
both thighs and
buttocks,
paresthesias of
anal/genital area,
buttocks, foot
soles,
rectum/bladder
dysfunction
17M
No surgery, EBI
50Gy over 1M,
SAE 3M later
SD
Signiﬁcant regression
of symptoms since
SAE but still
paresthesias both foot
soles and moderate
bladder dysfunction,
daily oral pain
medication, oral
clodronate (800 mg
2/d) since treatment
FU: followup, rec.: recurrence, M: male/months, F: female, Y: years, intral.: intralesional, res.: resection, EBI: external beam irradiation, preop.: preoperative,
SAE: selective arterial embolization, Gy: Gray, NED: no evidence of disease, SD: stable disease.
and was treated by EBI. At last follow up the patient
showed incomplete paralysis of the ﬂexors and extensors
of the left foot and the tumor was still progressive. At
the time of writing of this report he was scheduled for
experimental denosumab (human RANK ligand antibody)
treatment. Case 17 showed a tumor regression after the
ﬁrst EBI but presented with a progress 21 months after
initial treatment. He received another EBI combined with
oral bisphosphonates (clodronate). At the last follow up
he had stable disease, was not in pain but still taking
bisphosphonates.
3.2. Pulmonary Metastases. For the detection of pulmonary
metastases patients alternately received chest X-rays and CT
scans of the chest every 6 months for the ﬁrst two years. In
case of suspicious ﬁndings or local recurrence a chest CT
scan was performed. Two patients with aﬀection of the spine
(cases 3 and 5) developed pulmonary metastases 13 and 16
months after primary treatment: case 3 two months after
local recurrence, case 5 without signs of recurrence. Both
were initially treated by dorsoventral (partial) vertebral body
resection and dorsal instrumentation. When the metastases
of case 3 were detected she also showed a local progress
with destruction of Th 7 to Th 9, tumor tissue surrounding
the thoracic aorta, displacement of the cava and heart,
and pleural and pericardial eﬀusion. She was treated by
incomplete resection of the metastases followed by EBI
and 4 cycles of chemotherapy (ifosfamid/cisplatin). At last
followup 70 months after the metastases she was doing well,
had stable metastases and local ﬁndings and was pregnant.
Case 5 presented with unspeciﬁc ﬁndings in the chest CT
sinceﬁrstdiagnosis.16monthslaterthepulmonaryﬁndings,
were progressive and were conﬁrmed to be metastases after
surgical resection. At last followup she had no evidence of
disease, was doing well and taking oral bisphosphonates
(clodronate) since the last surgery.6 Sarcoma
(a) (b)
Figure 1: X-ray after dorsoventral spondylectomy. Postoperative X-ray of case 6. Dorsoventral intralesional spondylectomy of L4, dorsal
instrumentation from L3 to L5, and titanium cage interposition with bone graft.
Figure 2: X-ray after curettage and bone cement packing of a sacral
tumor. Postoperative X-ray of case 14 after intralesional curettage
and bone cement packing.
3.3. Clinical Outcome. At last followup 9 patients (3 spine, 6
sacrum)hadnoevidenceofdisease,8(2spine,6sacrum)had
stable disease, 1 (sacrum) progressive disease, and 1 (spine)
died due to disease. Besides the complications mentioned
abovetwopatients(case8and12)developedalocalinfection
aftercurettageofasacraltumorandweresuccessfullytreated
by systemic antibiotics and repeated surgical revisions.
Concerning the spine three patients were free of com-
plaints, one (case 6) was on daily pain medication and
one (case 1) had neurological impairments. Concerning the
sacrum, 8 patients were free of complaints, and ﬁve (cases 7,
9, 11, 16, 19) had neurological impairments (Table 1).
4. Discussion
In giant cell tumor of bone aﬀection of the axial skeleton is
extremely rare. From our database comprising 282 patients
only 6.7% occurred in the spine or sacrum. Thus they are
even less frequent than GCT of the pelvis with 8.7% of
our patients. This is in accordance with previous reports
[19, 22, 25]. It is known that GCT slightly prefer females
w i t har a t i oa r o u n d1 . 2t o1[ 1, 4, 6, 7, 27]. For the axial
skeleton 13 of our 19 patients (68.4%) were female which
is a much higher rate and in contrast to most previous
reports [19, 22]. Sanjay published a comparable gender
predilection for GCT of the spine [25]. Our patients with
a tumor of the mobile spine were younger than sacrum
patients or patients with tumors of the long bones, which
is in contrast to previous reports [19, 25]. Due to the small
amount of patients this might be incidental. In the study
by Martin and McCarthy [19] comprising 23 patients of
the spine and sacrum the minority of 10 patients aﬀected
the sacrum. In contrast to this in our study aﬀection of the
sacrum was more frequent than of the mobile spine. In the
publication by Sanjay et al. from 1993 about 24 patients with
GCT of the spine treated at the Mayo Clinic [25]a ﬀection
of the cervical, thoracic, and lumbar regions was equally
distributed. In our patient collective as in the case series
by Ma et al. from 1987 GCT only occurred in the thoracic
and lumbar spines [28]. The local recurrence rates of 66.7%
(4 of 6) for the mobile spine and 15.4% (2 of 13) for the
sacrum are signiﬁcantly higher than that of GCT of the
long bones or pelvis [1, 18, 29]. This is in accordance with
previous reports of Martin and McCarthy who published aSarcoma 7
(a) (b)
Figure 3: Angiogram before and after selective arterial embolization. (a) Preembolization angiogram of the right internal iliac artery
demonstratingamassivehypervascularizationofthegiantcelltumor(case6).(b)Afterembolizationwithembozenemicrospheres(250µm)
a complete devascularization of the giant cell tumor was achieved.
recurrence rate of 22% for sacral and 31% for spinal GCT
[19]andSanjayetal.whopublishedarateof41.7%forspinal
GCT [25]. Especially for intralesional resections or tumors
that have been solely treated by irradiation it is a matter of
deﬁnition to diﬀerentiate between recurrence or progress of
left-over tumor tissue. However, the statement of Martin and
McCarthy [19] that GCT of the axial skeleton, especially of
the spine, carry a much worse prognosis, can be aﬃrmed.
The rate of grade III tumors according to Campanacci
and Enneking [2, 26] as well as the rate of soft tissue
extension is higher than in patients with typical GCT [1, 2, 6,
30, 31]. The diagnosis might be delayed as the ﬁrst symptom
back pain is extremely frequent in the orthopaedic practice
and can easily be misinterpreted. On the other hand it might
beassumedthatthetumorsofthespineandsacrumaremore
aggressive.
As described for GCT of the long bones, tumors of
the axial skeleton are also capable of producing benign
pulmonary metastases. In our collective this occurred in two
of six patients with aﬀection of the spine and in none of the
sacrum cases. Whereas for typical GCT the metastasis rate of
less than 2% [1, 29] is extremely low it seems to be higher
for spinal tumors with published rates of up to 13.7% [24].
In contrast to this Martin and McCarthy did not ﬁnd any
metastases in 10 sacral and 13 spinal GCT [19].
Treatment strategies for typical GCT of the long bones
are generally well deﬁned. Treatment of choice is intrale-
sional curettage, burring of the cavity, and packing with
bone cement. This procedure in the majority of cases leads
to a good functional outcome with a local recurrence rate
of around 15% [1, 29, 31, 32]. However, this strategy can
hardlybetransferredtotumorsofthespineorsacrum.These
tumors often inﬁltrate the spinal canal, compressing the
spinal cord. Thus complete curettage is hardly possible and
adjunctssuchasbonecement,phenol,orcryotherapycannot
be used. Therefore in three sacral cases we decided not to
oﬀer surgery (case 17–19). All three presented with large
tumors very close to the neural structures. Surgical removal
would have resulted in severe neural damage. Nowadays we
wouldpreferablyperformSAEinsteadofprimaryirradiation
whenever surgery is not reasonable. Local recurrences of
the spine are much more diﬃcult to treat than of the
extremities. Additionally, tumors of the axial skeleton seem
to be diagnosed at a later stage of disease often presenting
with a soft tissue mass. Wide or marginal excision of the
t u m o ro re nb l o cr e s e c t i o n sm a yr e s u l ti nal o w e rr e c u r r e n c e
rate but often cause unacceptable neurological impairments
[19]. Liljenqvist et al. stated in a publication on malignant
tumors of the spine that en bloc spondylectomy enables
wide or marginal resection in most cases with acceptable
morbidity [33].
Four of our six spine patients had a local recurrence.
Although one of them received spondylectomy, the margins
were deﬁned as intralesional in all cases due to soft tissue
expansion and compression of the spinal cord or nerve roots.
This might explain the recurrence also after spondylectomy,
which is generally lower than after partial resections [19, 23,
25]. After review of the literature we also recommend en-
bloc resection whenever possible as this results in the lowest
recurrence rates even if not conﬁrmed by our results. We
nowadays aim for at least marginal en bloc spondylectomy
whenever possible.
T h er e c u r r e n c ei sa l w a y sm o r ed i ﬃcult to treat than
the primary tumor, thus its occurrence should be avoided
as much as possible. Serial SAE seems to be a treatment
option even if the tumor aﬀects the mobile spine. This
procedure was originally described for sacral tumors by Lin
et al. in 2002 [34]. He treated 18 patients with GCT of the
sacrum with a series of selective intra-arterial embolization
as sole treatment. Half of the patients showed a durable
radiographic response at long-term followup. Later Hosalkar
et al. published in 2007 [35] the successful treatment of8 Sarcoma
large GCT of the sacrum by repeated embolization. Nine
consecutive patients underwent angiography and SAE at
time of diagnosis, followed by repeated embolization every
6 weeks until no new vessels were noted, and then 6 and 18
months thereafter. With this procedure tumor progression
wasstoppedin7of9cases[35].Weadaptedthisprocedureto
treat a surgically inaccessible local recurrence of the lumbar
spine (case 6). The patient presented with a local recurrence
encasing the abdominal aorta with loss of sensory function
at L4 level 9 months after dorsoventral tumor resection. We
decidedtotreathimwithserialSAEdirectlyafterdetectionof
therecurrenceuntilcompletedevascularizationwasachieved
(Figure 3). This procedure was repeated after one and
six months. After the SAE the neurological impairments
completely recovered and the tumor is stable for 19 months
now. This is the ﬁrst description of successful treatment of a
spinalGCTwithserialSAEwhichmightbeadoptedforother
patients.
In the sacrum most cases were successfully treated by
intralesional curettage and bone cement packing. The high
recurrence rate of 48% of sacral tumors treated by curettage
alone published by Leggon et al. [12]w a sn o tc o n ﬁ r m e db y
our data. Possibly our recurrence rate was lower due to the
useofcementationwheneverpossibleandSAEinsomecases.
The role of EBI as primary or adjunct treatment is still
controversially discussed. Despite the relatively high risk of
radiation-induced malignancy [36–40], it is still used by
many. Leggon et al. published a rate of secondary sarcoma of
11% of patients with pelvic or sacral tumors [12], and Sanjay
etal.of25%inGCTofthepelvis[14].Oneofourspinecases
(case3)andoneofoursacrumcases(case9)receivedEBIfor
adjuvant treatment of a local recurrence. Three patients with
sacral tumors received EBI as an adjunct to initial surgery
(cases 12, 15, 16), three as primary treatment (cases 17–19).
None of them developed a secondary malignancy so far but
as the risk increases with time [41] it might occur at a longer
followup. When surgery is an option irradiation should be
avoided. Even in inaccessible tumors we by now prefer SAE
before considering EBI.
Whereas uncommon for typical GCT a relatively high
rate of patients with tumors of the axial skeleton suﬀer
from neurological impairments either at diagnosis or due
to therapy. Three of our spine (cases 3, 5, 6) and two
of our sacrum patients (cases 16 and 19) had deﬁcits at
ﬁrst presentation. For the spine this rate is in accordance
with previous reports of 50 to 70% [19, 22, 25]w h e r e a s
for the sacrum it seems to be lower. All of our spine
patients recovered from their impairments after treatment
whereas in the sacrum the deﬁcits were persistent. One
spine patient (case 1) developed a loss of sensory function
and paresthesias, one sacrum patient (case 7) developed
neurological claw toes, another (case 11) a conus/cauda
syndrome after surgery. One patient (case 9) developed a
footdrop due to progress of a sacral tumor. Thus compared
to GCT of the long bones, surgical treatment is accompanied
by a high risk of neurological deﬁcits.
Although the recent literature describes positive eﬀects
of systemic bisphosphonate administration [42–44], their
role in therapy of GCT is still not fully understood. Due
to the dismal prognosis of GCT of the spine and sacrum
and the relatively rare side eﬀects we nowadays recommend
additional bisphosphonates in complicated cases and metas-
tases. Whether there really is an eﬀect has to be answered in
the future. A promising agent which is increasingly used in
GCT is denosumab, a human monoclonal antibody against
RANK ligand, which is able to inhibit osteoclast function.
In 2010 Thomas et al. investigated its eﬀect on tumor-cell
survival and tumor growth in patients with recurrent or
unresectable GCT and found that 86% had a tumor response
[45]. Although its eﬀect has to be proven in larger and
independent studies, denosumab might be a new treatment
option especially in complicated cases.
Although some authors advocate treatment algorithms
for spinal [46] and sacral [22] tumors, the decision still has
to be made for each case individually. Case presentations
such as presented here are the only published references
when treating these rare tumors, and are of high impor-
tance. In our study as in all other published case series
the diﬀerent treatment regimens were very heterogeneous,
ranging from conservative treatments such as SAE or EBI
to en bloc spondylectomy. Statistical analysis of diﬀerent
treatment modalities is impossible. However, the published
experiences of successful therapies might be transferred to
other patients. Whereas spinal tumors should be treated
moreaggressivelyintralesionalcurettageseemstobeeﬀective
in sacral tumors. Whenever surgery is not possible selective
arterial embolization might be considered even for GCT of
the spine.
5. Conclusion
Compared to the long bones GCT of the axial skeleton has to
be considered as a severe disease with a high local recurrence
rate. Neurological deﬁcits caused by the tumor itself or its
treatment are common. En bloc spondylectomy combined
with embolization is the treatment of choice whenever
possible. In case of inoperability serial arterial embolization
seems to be an alternative not just for tumors of the sacrum
but also of the mobile spine.
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